SALT LAKE CITY, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced enhancements to the GeneSight ® Psychotropic test, ...

Recently, Myriad Genetics, Inc.’s MYGN myChoice CDx test has been added under the American Society of Clinical Oncology’s (“ASCO”) latest recommendations on the use of PARP inhibitors for treatment ...

Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...

Human Geneticist Dr. Neville Sanjana answers the internet’s burning questions about genetics and DNA. How are our genes related to our DNA? Does our DNA change during our lifetime? How do services ...

Myriad Genetics, Inc. (NASDAQ:MYGN) announced that its Vectra test was included by the American College of Rheumatology (“ACR”) in its list of recommended disease activity measures for patients with ...

Every time Emma publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from Business ...

The Target-MRD blood test uses a combination of tumor-informed and tumor-agnostic molecular features for personalized, accurate and more effective monitoring of molecular residual disease. In patients ...

The United States and Japan reaffirmed their commitment to "market determined" exchange rates, while agreeing that foreign exchange interventions should be reserved for combating excess volatility, ...